RCE Shares Recce Pharmaceuticals Ltd
ASX · ASXLast in our picks 2026-10-25 — not in the current list; analysis below is from that screen
Antibiotic pipeline offers differentiated resistance-focused upside with multiple clinical development milestones.
Future value: $0.55 (+64.18%) · 6-12 months
Signal breakdown
- ▸Clinical pipeline progress and recent positive share-price momentum.
- ▾Below 50-day MA (-1.14%)
- ▸~64% upside to price target
Is RCE a buy right now?
Trend: RCE is trading below the 50-day average (-8.82%), RSI 41 — neutral momentum, with a 3-month return of -17.33%.
Valuation & quality: Recce Pharmaceuticals Ltd trades on forward P/E 16.3; fundamentals show net margin -158.1%, revenue growth 1509.5% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$2.55 (+722.6% vs the last close; range A$2.55 – A$2.55), consensus rating “strong buy”.
Our screen: BUY (score 2) — Antibiotic pipeline offers differentiated resistance-focused upside with multiple clinical development milestones.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -13.00% | +2.10% | +14.60% | -25.50% | -9.80% | +2.70% | -18.40% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.